Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Farletuzumab

Phase 2Monoclonal antibody

Farletuzumab is one of 107 small molecule programs targeting Adenoma. It is currently in Phase 2.

3

Indications

5

Total Trials

0

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Ovarian CancerActive, not recruiting

AdenomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Avastin

BBio-Thera Solutions

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cytoxan

BBaxter Healthcare Corporation

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Zepzelca

Jazz Pharmaceuticals

Nolvadex

Taxotere

Yondelis

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer3 trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated·MMorphotek·Phase 3·NCT00849667·1,100 enrolled

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Completed·MMorphotek·Phase 2·NCT00318370·58 enrolled

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Completed· Eisai logo

Eisai·Phase 2·NCT02289950·332 enrolled

Adenoma1 trial

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Withdrawn·MMorphotek·Phase 2·NCT01203618

Adenocarcinoma1 trial

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Completed·MMorphotek·Phase 2·NCT01218516·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Farletuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Farletuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Farletuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Eisai

Related News